Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
Recruiting · NCT06092086 · Registry updated 2023-10-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC | ALK Positive Non-small Cell Lung Cancer | Recruiting | Phase 2 | 2023-10-23 | NCT06092086 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Guangdong Association of Clinical Trials | 20 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Guangdong Provincial Perople's Hospital | Guangzhou | China | 1 |